Pfizer Looks to FDA to Give Vaccine the Go-Ahead ‘Within Days’

We Americans have been a patient people as of the last several months, hoping and praying that an end to this coronavirus nightmare would be coming soon.

Not only are an incredible number of us being personally affected by this horrific disease, but the need for social distancing has shuttered countless businesses from coast to coast, and shoved a great many Americans into the unemployment line.

Now, with just a few weeks left in the year from hell, Pfizer looks poised to swoop in and save us…with the FDA’s approval, of course.

Pfizer is ready to ask the Food and Drug Administration to authorize emergency use of the company’s COVID-19 vaccine, after an updated analysis of the clinical trial data found the vaccine to be 95% effective.

The results from the final efficacy analysis of the vaccine study were released Wednesday. An interim analysis released Nov. 9 had indicated the vaccine was more than 90% effective.

In the Phase 3 study involving more than 43,000 volunteers, half received the experimental vaccine and half got a placebo. Participants received two shots, spaced 21 days apart.

And, as if to place an exclamation point at the end of this good-feeling story:

The companies said the vaccine’s efficacy held up across gender, race, ethnicity and various ages. In people older than 65, a group at elevated risk from COVID-19, the efficacy was 94%.